Format

Send to

Choose Destination
Muscle Nerve. 2009 Feb;39(2):137-43. doi: 10.1002/mus.21213.

Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.

Author information

1
University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 7883, San Antonio, Texas 78229-3900, USA. jacksonce@uthscsa.edu

Abstract

Twenty ALS patients with sialorrhea refractory to medical therapy were enrolled in this double-blind, randomized study to receive either 2,500 U of botulinum toxin type B (BTxb) or placebo into the bilateral parotid and submandibular glands using electromyographic guidance. Patients who received BTxb reported a global impression of improvement of 82% at 2 weeks compared to 38% of those who received placebo (P < 0.05). This significant effect was sustained at 4 weeks. At 12 weeks, 50% of patients who received BTxb continued to report improvement compared to 14% of those who received placebo. There were no significant adverse events, including dysphagia, in the BTxb group, and there was no significant increase in the rate of decline of vital capacity.

PMID:
19145653
DOI:
10.1002/mus.21213
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center